Promising Outlook for vTv Therapeutics: Buy Rating Affirmed Amidst Advancements in Type 1 Diabetes Treatment
I'm PortAI, I can summarize articles.
H.C. Wainwright analyst Emily Bodnar has reaffirmed a Buy rating on vTv Therapeutics with a price target of $36.00, citing positive developments in the company's Phase 3 CATT1 trial for Type 1 diabetes treatment. All 23 trial sites are activated, with patient enrollment expected to finish by Q1 2026. Recent $80 million PIPE financing supports the trial's progress, and the FDA has lifted a clinical hold. Promising results from earlier studies and Breakthrough Therapy Designation further enhance the outlook for cadisegliatin as a potential treatment.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments